Grifols Completes Acquisition of Biotest Shares Following Delisting

Grifols SA ( (GRFS) ) has issued an update.

On June 11, 2025, Grifols, S.A. announced the completion of its public delisting offer for Biotest Aktiengesellschaft, resulting in Grifols holding 99.25% of Biotest’s voting ordinary shares and 61.40% of its non-voting preferred shares. The delisting offer, which ended on June 6, 2025, involved a total payment of €108,011,766 for the acquired shares. This strategic move consolidates Grifols’ position in the biopharmaceutical industry by expanding its control over Biotest, following the delisting of Biotest shares from the Frankfurt Stock Exchange.

The most recent analyst rating on (GRFS) stock is a Buy with a $15.45 price target. To see the full list of analyst forecasts on Grifols SA stock, see the GRFS Stock Forecast page.

Spark’s Take on GRFS Stock

According to Spark, TipRanks’ AI Analyst, GRFS is a Neutral.

Grifols SA’s overall score reflects strong financial performance improvements and robust earnings, tempered by high leverage and valuation concerns. Technical indicators show bullish momentum but caution due to overbought signals. The earnings call confirmed positive growth trends, despite cash flow challenges.

To see Spark’s full report on GRFS stock, click here.

More about Grifols SA

Grifols, S.A. is a global healthcare company based in Barcelona, Spain, specializing in the production of plasma-derived medicines and transfusion medicine. The company focuses on enhancing patient care and providing innovative solutions in the healthcare sector.

Average Trading Volume: 862,553

Technical Sentiment Signal: Buy

Current Market Cap: $7.41B

See more insights into GRFS stock on TipRanks’ Stock Analysis page.